Cited by 799Advanced Proteomics Techniques and ApplicationsCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers

Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities

Open access
Vasaikar, Suhas, Huang, Chen, Wang, Xiaojing, Petyuk, Vladislav A., Savage, Sara R., Wen, Bo, Dou, Yongchao, Zhang, Yun +74 more·2019·Cell

Abstract

We performed the first proteogenomic study on a prospectively collected colon cancer cohort. Comparative proteomic and phosphoproteomic analysis of paired tumor and normal adjacent tissues produced a catalog of colon cancer-associated proteins and phosphosites, including known and putative new biomarkers, drug targets, and cancer/testis antigens. Proteogenomic integration not only prioritized genomically inferred targets, such as copy-number drivers and mutation-derived neoantigens, but also yielded novel findings. Phosphoproteomics data associated Rb phosphorylation with increased proliferation and decreased apoptosis in colon cancer, which explains why this classical tumor suppressor is amplified in colon tumors and suggests a rationale for targeting Rb phosphorylation in colon cancer. Proteomics identified an association between decreased CD8 T cell infiltration and increased glycolysis in microsatellite instability-high (MSI-H) tumors, suggesting glycolysis as a potential target to overcome the resistance of MSI-H tumors to immune checkpoint blockade. Proteogenomics presents new avenues for biological discoveries and therapeutic development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2019.03.030

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CPTAC and ICPC collaborators have comprehensively characterized 13 cancer types at the proteogenomics level, with all datasets publicly accessible.

    “Collectively, CPTAC and ICPC collaborators have comprehensively characterized 13 cancer types at the proteogenomics level, with all datasets publicly accessible109–117.”

    From A high-stringency blueprint of the human proteome (2020) · cites this paper as [112]

  • The flagship efforts of the Cancer Proteomics Consortium, CPTAC, have brought targeted proteomics and proteogenomics into regular use and produced major studies on ovarian, breast, and colorectal cancer.

    “The flagship efforts of the Cancer Proteomics Consortium, CPTAC, have brought targeted proteomics and proteogenomics into regular use and produced major studies on ovarian ( 10 ), breast ( 11 ), and colorectal cancer ( 12 ).”

    From The Human Proteoform Project: Defining the human proteome (2021) · cites this paper as [12]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Vasaikar, S., Huang, C., Wang, X., Petyuk, V. A., Savage, S. R., Wen, B., Dou, Y., Zhang, Y., Shi, Z., Arshad, O. A., Gritsenko, M. A., Zimmerman, L. J., McDermott, J. E., Clauss, T. R., Moore, R. J., Zhao, R., Monroe, M. E., Wang, Y.-T., Chambers, M. C., Slebos, R. J. C., Lau, K. S., Mo, Q., Ding, L., Ellis, M., Thiagarajan, M., Kinsinger, C. R., Rodriguez, H., Smith, R. D., Rodland, K. D., Liebler, D. C., Liu, T., Zhang, B., Pandey, A., Paulovich, A., Hoofnagle, A., Mani, D. R., Chan, D. W., Ransohoff, D. F., Fenyo, D., Tabb, D. L., Levine, D. A., Boja, E. S., Kuhn, E., White, F. M., Whiteley, G. A., Zhu, H., Zhang, H., Shih, I.-M., Bavarva, J., Whiteaker, J., Ketchum, K. A., Clauser, K. R., Ruggles, K., Elburn, K., Hannick, L., Watson, M., Oberti, M., Mesri, M., Sanders, M. E., Borucki, M., Gillette, M. A., Snyder, M., Edwards, N. J., Vatanian, N., Rudnick, P. A., McGarvey, P. B., Mertins, P., Townsend, R. R., Thangudu, R. R., Rivers, R. C., Payne, S. H., Davies, S. R., Cai, S., Stein, S. E., Carr, S. A., Skates, S. J., Madhavan, S., Hiltke, T., Chen, X., Zhao, Y., Wang, Y., & Zhang, Z.
Affiliations
  • Baylor College of Medicine (US)
  • Pacific Northwest National Laboratory (US)
  • Vanderbilt University Medical Center (US)
  • Vanderbilt University (US)
  • Washington University in St. Louis (US)
  • Frederick National Laboratory for Cancer Research (US)
  • National Cancer Institute (US)
Corresponding author
  • Rodland, Karin D.
  • Liebler, Daniel C.
  • Liu, Tao
  • Zhang, Bing
Venue
Cell
Publisher
Elsevier BV
Published
2019-05
Volume
177
Issue
4
Pages
1035-1049.e19
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2940627982
Cited by
799
References
81
Citations by year
2026: 85 · 2025: 102 · 2024: 103 · 2023: 123 · 2022: 137 · 2021: 128 · 2020: 91 · 2019: 29
FWCI
39.43
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (acceptedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
Funders
  • Robert and Janice McNair Foundation
  • National Cancer Institute
  • Cancer Prevention and Research Institute of Texas
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
colon cancer, proteogenomics, phosphoproteomics, tumor-associated proteins, phosphosites, biomarkers, therapeutic target, cancer-testis antigens, neoantigens, retinoblastoma protein phosphorylation, CD8+ T cell infiltration, glycolysis, microsatellite instability-high, immune checkpoint inhibitor resistance
MeSH terms
Proteogenomics, Colonic Neoplasms, Glycolysis, Humans, Mutation, Phosphorylation, Prospective Studies, Biomarkers, Tumor, Retinoblastoma Protein, Apoptosis, CD8-Positive T-Lymphocytes, Genomics, Proteomics, Cell Proliferation, Microsatellite Instability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review